Summary
Summary BNF Drug Summaries - Cardiovascular System
A 14-page concise summary of the cardiovascular system intended to facilitate preparation for the GPhC registration exam. These notes can also be used as a quick reference guide or a resource to refresh general clinical pharmacy knowledge, perfect for pre-registration pharmacists, medical students,...
[Show more]
Preview 2 out of 14 pages
Summarized whole book?
No
Which chapters are summarized?
Chapter 2 - cardiovascular system
Uploaded on
June 8, 2021
Number of pages
14
Written in
2020/2021
Type
Summary
By: ti2651999 • 2 year ago
£5.48
Also available in package deal from £10.48
100% satisfaction guarantee
Immediately available after payment
Both online and in PDF
No strings attached
Also available in package deal (1)
1. Summary - Bnf drug summaries - gastrointestinal system
2. Summary - Bnf drug summaries - cardiovascular system
3. Summary - Bnf drug summaries - respiratory system
4. Summary - Bnf drug summaries - nervous system
5. Summary - Bnf drug summaries - infection
6. Summary - Bnf drug summaries - endocrine system
7. Summary - Bnf drug summaries - genitourinary system
8. Summary - Bnf drug summaries - malignant disease
9. Summary - Bnf drug summaries - blood and nutrition
10. Summary - Bnf drug summaries - musculoskeletal system
11. Summary - Bnf drug summaries - eye
12. Summary - Bnf drug summaries - ear, nose and oropharynx
13. Summary - Bnf drug summaries - skin
14. Summary - Bnf drug summaries - vaccines
15. Summary - Bnf drug summaries - anaesthesia
16. Summary - Bnf drug summaries - emergency treatment of poisoning
17. Summary - Bnf drug summaries - miscellaneous
Show more
Drug Summaries – Humza Ibrahim
4.2.2 Long-term management ...................... 6
Chapter 2 5 Warfarin (high risk) .............................................. 7
Cardiovascular System 5.1 Target inr...................................................... 7
5.2 Duration ....................................................... 7
TABLE OF CONTENTS 5.3 Warning sings............................................... 7
5.4 Monitoring ................................................... 7
Table of Contents ......................................................... 1
5.5 Pregnancy and breastfeeding ...................... 7
1 Arrhythmias.......................................................... 3
5.6 Interactions .................................................. 7
1.1 Drugs for arrhythmias .................................. 3
5.7 Hepatic impairment ..................................... 7
1.1.1 Drug treatment .................................... 3
5.8 Renal impairment ........................................ 7
1.1.2 Cardioversion ....................................... 3
5.9 Other points ................................................. 7
1.1.3 Stroke prevention ................................ 3
6 Antiplatelet drugs ................................................ 8
1.2 Amiodarone (high risk)................................ 4
6.1 Aspirin .......................................................... 8
1.2.1 Warning signs ....................................... 4
6.1.1 Reye's syndrome (liver and brain
1.2.2 Monitoring ........................................... 4 damage) 8
1.2.3 Pregnancy............................................. 4 6.1.2 Hypersensitivity ................................... 8
1.2.4 Breastfeeding ....................................... 4 6.2 Oral antiplatelets (high risk) ....................... 8
1.2.5 Drug Interactions ................................. 4 6.2.1 Warning signs....................................... 8
1.3 Sotalol .......................................................... 4 6.2.2 Monitoring ........................................... 8
1.3.1 Safety information ............................... 4 6.2.1 Other points ......................................... 8
1.3.2 Monitoring ........................................... 4 6.2.2 Interactions .......................................... 8
2 Cardiac Glycosides ............................................... 5 7 Hypertension ....................................................... 8
2.1 Digoxin (High Risk)....................................... 5 7.1 Thresholds.................................................... 8
2.1.1 Warning signs ....................................... 5 7.2 Targets for treatment .................................. 9
2.1.2 Monitoring ........................................... 5 7.3 Drug treatment (NICE 2107) ........................ 9
2.1.3 Renal impairment................................. 5 7.4 Reducing cardiovascular risk........................ 9
2.1.4 Drug interactions.................................. 5 7.5 Diabetes and renal disease .......................... 9
3 Venous Thromboembolism .................................. 5 7.6 Hypertension and pregnancy....................... 9
3.1 Prophylaxis ................................................... 5 7.7 Hypertensive crisis ....................................... 9
3.2 Treatment .................................................... 5 7.8 Antihypertensives (high risk) ...................... 9
3.3 Pregnancy..................................................... 5 7.8.1 Warning signs....................................... 9
3.4 Haemorrhage ............................................... 6 7.8.2 Monitoring ........................................... 9
3.5 Heparin......................................................... 6 7.8.3 Interactions .......................................... 9
3.5.1 Heparin-induced thrombocytopenia ... 6 7.8.4 Other points ......................................... 9
3.5.2 Hyperkalaemia ..................................... 6 7.9 Drugs affecting the renin-angiotensin
4 Stroke ................................................................... 6 system 10
4.1 Transient ischaemic attack........................... 6 7.9.1 Initiation under specialist supervision10
4.2 Ischaemic stroke .......................................... 6 7.9.2 Renal effects ...................................... 10
4.2.1 Initial management .............................. 6 7.9.3 Cautions ............................................. 10
7.10 Beta-adrenoceptor blocking drugs ............ 10
Chapter 2 – Pg 1
Compiled using the British National Formulary
, Drug Summaries – Humza Ibrahim
7.11 Calcium channel blockers........................... 11
7.12 Hypotension and shock .............................. 11
8 Heart failure ....................................................... 11
9 Hyperlipidaemia ................................................. 11
9.1 Risk calculators........................................... 11
9.2 Primary and secondary prevention of
cardiovascular disease ........................................... 11
9.3 Cholesterol tests ........................................ 12
9.4 Hypercholesterolaemia,
hypertriglyceridaemia, and familial
hypercholesterolaemia .......................................... 12
9.5 Statins......................................................... 12
10 Stable angina ...................................................... 12
11 Acute coronary syndromes (ACS) ...................... 12
11.1 Initial management of unstable angina,
nstemi and stemi.................................................... 12
11.1.1 Additional acute management of
unstable angina, NSTEMI ................................... 13
11.1.2 Additional acute management of STEMI
13
11.2 Long-term management ACS ..................... 13
11.3 Nitrates....................................................... 13
11.4 Fibrinolytics ................................................ 13
12 Oedema .............................................................. 13
12.1 Elderly ........................................................ 13
12.2 Potassium loss ............................................ 13
12.3 Urinary retention ....................................... 13
12.4 Diabetes and gout ...................................... 13
12.5 Diuretics (high risk).................................... 14
12.5.1 Warning signs ..................................... 14
12.5.2 Monitoring ......................................... 14
12.5.3 Other points ....................................... 14
12.5.4 Interactions ........................................ 14
Chapter 2 – Pg 2
Compiled using the British National Formulary